{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:51:21Z","timestamp":1787021481379,"version":"build-2736575974"},"reference-count":0,"publisher":"Frontline Medical Communications, Inc.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.12788\/cutis.0632","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T11:54:31Z","timestamp":1665575671000},"source":"Crossref","is-referenced-by-count":3,"title":["Vedolizumab-Induced Acne Fulminans: An Uncommon and Severe Adverse Effect"],"prefix":"10.12788","volume":"110","author":[{"family":"Blankenship","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5043","published-online":{"date-parts":[[2022,9]]},"container-title":["Cutis"],"original-title":[],"link":[{"URL":"https:\/\/cdn.mdedge.com\/files\/s3fs-public\/CT110003019_e.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T11:54:31Z","timestamp":1665575671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdedge.com\/dermatology\/article\/258465\/acne\/vedolizumab-induced-acne-fulminans-uncommon-and-severe-adverse"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"URL":"https:\/\/doi.org\/10.12788\/cutis.0632","relation":{},"subject":[],"published":{"date-parts":[[2022]]}}}